ILMN Q3 Earnings Preview: Strong Clinical Demand May Lift Performance

Illumina's Q3 results may benefit from strong clinical demand, NovaSeq X adoption, instrument placements and innovations despite persistent weakness in research markets.

Zacks Investment Research • 6 hours ago

Illumina (ILMN) Reports Next Week: Wall Street Expects Earnings Growth

Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • 5 hours ago

Illumina: NovaSeq X And Consumables Sustain Momentum

Illumina (ILMN) is rated a Buy, driven by robust demand for consumables and NovaSeq X instruments, supported by favorable market dynamics and regulatory tailwinds. NovaSeq X accounts for 59% of consumable revenues, up from 44% in Q2'25, highlighting strong uptake and positioning ILMN to capture expanding diagnostic consumables market share. Management guides for FY2026 revenue of $4.60–$4.64 billion and analysts expect EPS of $5.36, reflecting double-digit upside with a fair forward P/S target of 9.75x ($293.77).

Seeking Alpha • 6 hours ago

Illumina BioInsight Platform expands with new software to accelerate the path from sequencing to discovery

DRAGEN Ultra, BioInsight Platform Workflow Orchestrator, and BioInsight Platform Learning Cohorts are now available in early access, incorporating new AI-driven approaches to analysis, automation, and discovery The tools automate end-to-end informatics processes at scale and help customers build private data lakes to drive scientific and clinical research insights SAN DIEGO, Oct. 21, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today introduced three early-access capabilities on its BioInsight Platform that help researchers move faster from sequencing data to discovery. BioInsight Platform Workflow Orchestrator enables laboratories to operate consistent, traceable sequencing and informatics operations at scale.

PRNewsWire • Oct 21, 2026

Illumina To Webcast Upcoming Investor Conference

SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that members of its management team will participate at the following investor conference: Upcoming Investor Conference UBS Global Healthcare Conference on November 10, 2026 The fireside chat is scheduled for 07:15am PT (10:15am ET). The webcast can be accessed through the Events & Presentations section of Illumina's website at investor.illumina.com.

PRNewsWire • Oct 20, 2026

The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning

Rate and energy headlines have kept the broad market jumpy, yet one sector keeps finding buyers. Healthcare has led on days when the S&P 500 slipped, and the Nasdaq Biotechnology Index has pushed to record highs.

MarketBeat • Oct 19, 2026

Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report?

Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research • Oct 16, 2026

Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs

The new platform brings together advanced analysis, purpose-built AI, and curated biological data so researchers can move more quickly from complex genomic and multiomic data to actionable insight Included in the new platform, latest DRAGEN update expands access to Illumina's award-winning secondary analysis across supported cloud and standard computing environment SAN DIEGO, Oct. 14, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today debuted the Illumina BioInsight Platform, the company's first unified software environment designed to help researchers turn complex genomic and multiomic data into meaningful biological evidence. By bringing together Illumina's analysis applications, purpose-built AI innovations, and curated data resources in one environment, the platform delivers flexibility and accessibility, while reducing the need to assemble and manage separate informatics tools as research questions evolve.

PRNewsWire • Oct 14, 2026

Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026

SAN DIEGO, Oct. 8, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the third quarter 2026 following the close of market on Thursday, October 29, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

PRNewsWire • Oct 8, 2026

Illumina releases SpliceAI2 to help advance rare disease research

In a rare disease research dataset, SpliceAI2 identified 17% more disease-relevant variants compared to other splicing models Illumina's genomic AI models now collectively enable researchers to identify 2x as many variants with predicted biological impact SAN DIEGO, Oct. 8, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today introduced SpliceAI2, a new genomic AI model designed to address one of the central challenges in genomics: understanding the functional consequences of genetic variation. SpliceAI2 helps researchers identify disease-relevant splice variants that otherwise may go unnoticed.

PRNewsWire • Oct 8, 2026